Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection.
about
Human immunodeficiency virus & cardiovascular riskChanges in lipids over twelve months after initiating protease inhibitor therapy among persons treated for HIV/AIDSNevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatmentFuture directions: lung aging, inflammation, and human immunodeficiency virusMarkers of coagulation and inflammation often remain elevated in ART-treated HIV-infected patientsArterial disease in patients with human immunodeficiency virus infection: what has imaging taught us?HIV Infection in the Elderly: Arising ChallengesHIV protease inhibitors: a review of molecular selectivity and toxicitySevere morbidity according to sex in the era of combined antiretroviral therapy: the ANRS CO3 Aquitaine CohortMyocarditis in CD8-depleted SIV-infected rhesus macaques after short-term dual therapy with nucleoside and nucleotide reverse transcriptase inhibitorsAtherosclerotic Cardiovascular Disease and Anti-Retroviral Therapy.The role of lopinavir/ritonavir (Kaletra) in the management of HIV infected adults.Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular risk.Retrivability in The Danish National Hospital Registry of HIV and hepatitis B and C coinfection diagnoses of patients managed in HIV centers 1995-2004.Heart Disease in Patients with HIV/AIDS-An Emerging Clinical Problem.Risk of myocardial infarction in parents of HIV-infected Individuals: a population-based Cohort Study.Association between kidney function and albuminuria with cardiovascular events in HIV-infected personsInpatient health services utilization among HIV-infected adult patients in care 2002-2007.Microbial translocation and cardiometabolic risk factors in HIV infection.Effect of early versus deferred antiretroviral therapy for HIV on survival.Microvascular Endothelial Dysfunction and Enhanced Thromboxane and Endothelial Contractility in Patients with HIV.The consequences of HIV infection and antiretroviral therapy use for cardiovascular disease risk: shifting paradigms.Cardiovascular disease risk factors in HIV-infected women after initiation of lopinavir/ritonavir- and nevirapine-based antiretroviral therapy in Sub-Saharan Africa: A5208 (OCTANE)Epidemiology of coronary heart disease in patients with human immunodeficiency virusCardiovascular risk evaluation and antiretroviral therapy effects in an HIV cohort: implications for clinical management: the CREATE 1 study.Associations between HIV infection and subclinical coronary atherosclerosisHigh-fat meals do not impair postprandial endothelial function in HIV-infected and uninfected menHepatitis C progressing to hepatocellular carcinoma: the HCV dialysis patient in dilemma.Heart and HAART: Two sides of the coin for HIV-associated cardiology issuesImpaired diastolic function in naïve untreated human immunodeficiency virus infected patients.Perspective on HIV infection and aging: emerging research on the horizon.Diabetes, insulin resistance, and dementia among HIV-1-infected patientsRisk of cardiovascular disease from antiretroviral therapy for HIV: a systematic reviewPrevalence and prognostic significance of ECG abnormalities in HIV-infected patients: results from the Strategies for Management of Antiretroviral Therapy studyHepatitis C virus infection and the risk of coronary disease.HIV-1 and recombinant gp120 affect the survival and differentiation of human vessel wall-derived mesenchymal stem cells.HIV infection in the elderlyHepatitis C treatment completion rates in routine clinical care.Cigarette smoking in the HIV-infected population.
P2860
Q22241184-FF91AB0F-B992-42B6-ACEB-EA2B250DA95BQ24792952-412A556E-D5B4-4C75-BA0F-975A75AD08FFQ24802369-B60038BA-18A9-4723-8DEA-4FE594717395Q24803596-608E2DB4-E52F-4709-A9B7-2F970DE33C3AQ26996040-788E644E-2B6C-4AE4-B631-4EED896B52CAQ27024262-FCB0688A-CFFE-4731-8B16-3F8D7A4E1905Q27026486-130F3A91-4894-46B4-8647-E3F57165EB1FQ28076000-035FC160-CDEC-4373-AE6C-BD5E15133F4FQ28082749-B2683814-89B2-4064-A5CB-D9EB9EFEB042Q28541356-8A02330C-D4A8-4000-B4F6-42EC9881B47DQ28743987-652EB9BB-0245-4EBF-9075-1862D4317D8DQ30248286-D01097AB-5E7E-43F0-AE7B-9E2748FEC019Q30343901-122D9525-D725-468E-8555-EFAFC25BA8A0Q33330313-6BDB451B-1ADB-41AC-96AB-7123A52FF6DFQ33330995-0988815E-D0B4-41C3-AF19-7B46743B0976Q33587954-13E65143-E6DA-462A-9E56-412A383D2439Q33603728-F973706D-F265-4F27-ACA2-1919F092D4CBQ33692733-87E28698-9D64-45A6-9CEA-4778E5D99999Q33699011-1E5978E6-6884-4D17-8D02-56A8CF7ADE31Q33713895-22BE46FD-9F7A-46FA-AD0C-73763D2B5782Q33789114-37935177-E1AF-49F5-A6B3-651234064BB4Q33792101-9712E64B-A475-4741-8E84-AE1D3463BE0EQ33889580-D6F00008-75D9-4953-88E2-C439672C78C9Q33944936-0D0F9A82-4437-4EC2-AC7A-A1317222A45EQ33998067-B5CA6439-5245-49AA-A841-3E6CDD6585E8Q34032348-2EACD038-92EA-4F1B-98EA-8BED1B9ECC9FQ34085805-51C1DE08-1B83-4821-AEC8-E79829186585Q34116810-88B8F291-7F0C-44FC-A964-2E26257994F7Q34207872-1943FE9A-6848-4C29-862C-0D0588F3597DQ34390565-2CE7490E-3140-48D7-AFCB-5CDB2FFFE3A5Q34390648-65E6AFD9-0451-40FD-8A5C-BBFA3D346113Q34444007-A3754DE9-D829-452E-B406-D589981A4D6FQ34483421-7EEEDC08-EB10-421D-86B7-0F1890D214BDQ34651525-FE07992B-AA3A-4252-855A-9394094955D9Q34694448-CE67588C-EFC1-4E45-A244-E3B04B118000Q34802706-C519EEE9-1D1A-4F18-997D-3BB32A6FEEA7Q35068359-CEDC7372-951C-4CF9-97D7-F659228F05EAQ35086332-1E605173-CA63-4113-971B-102E2357C97EQ35093134-95566367-D7C1-40F8-9E08-A1AA0522B5CFQ35095054-2B5EB9B7-7B69-4295-B7C3-A340ECBAF881
P2860
Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Cardiovascular and cerebrovasc ...... unodeficiency virus infection.
@en
Cardiovascular and cerebrovasc ...... unodeficiency virus infection.
@nl
type
label
Cardiovascular and cerebrovasc ...... unodeficiency virus infection.
@en
Cardiovascular and cerebrovasc ...... unodeficiency virus infection.
@nl
prefLabel
Cardiovascular and cerebrovasc ...... unodeficiency virus infection.
@en
Cardiovascular and cerebrovasc ...... unodeficiency virus infection.
@nl
P2093
P356
P1476
Cardiovascular and cerebrovasc ...... unodeficiency virus infection.
@en
P2093
Christopher F Ake
Henry K Tam
Samuel A Bozzette
Sophia W Chang
Thomas A Louis
P304
P356
10.1056/NEJMOA022048
P407
P577
2003-02-01T00:00:00Z